South Korea–(Business Wire)–South Korea’s Biostar Stem Cell Research Institute (CEO: Jeong-Chan Ra), jointly operated by Nature Cell and Rbio, today announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12. The stem cell therapy of Alzheimer’s disease is to administer autologous adipose tissue-derived mesenchymal stem cells intravenously.Dr. Ra’s research team tested animals that have Alzheimer’s disease and proved the effectiveness of the stem cell treatment of Alzheimer’s disease as well as the prevention of Alzheimer’s disease. Unlike the existing treatment for Alzheimer’s disease that only slows the progression of the illness, stem cell therapy is expected to be a fundamental cure for the disease. Dr. Ra’s research team tested animals that have Alzheimer’s disease and proved the effectiveness of the stem cell treatment of Alzheimer’s disease as well as the prevention of Alzheimer’s disease. Dr. Ra’s study was also published in the international journal Plos-One in 2012, and the treatment is known to perform multiple functions including anti-inflammation, cerebral vascular regeneration, and brain cell protection and regeneration.
Nature Cell and Biostar Stem Cell Research Institute Begin World’s First Stem Cell-Based Regenerative Treatment for Alzheimer’s Disease in Japan
More from ResearchMore posts in Research »
- A possible blood test for early-stage Alzheimer’s disease | Medical Xpress
- Blood Biomarkers Plus Gene Status Predict Cognitive Decline : Neurology Today
- Early Detection of Alzheimer’s Prior to Onset of Symptoms Now Possible | Science Times
- We Need New Ideas for Fighting Alzheimer’s | Scientific American
- Immune view offers clues to early Alzheimer’s